文章核心观点 - Zacks Premium为投资者提供利用股市和自信投资的途径，其Zacks Style Scores和Zacks Rank结合可助投资者选到优质股票，如United Therapeutics值得关注 [1][2][11] Zacks Style Scores相关 整体介绍 - Zacks Style Scores是一套独特准则，基于三种投资类型对股票评级，作为Zacks Rank补充指标，助投资者选未来30天跑赢市场的证券 [2] - 按价值、增长、动量特征，股票被评为A、B、C、D或F，分数越好跑赢几率越高 [14] 分类情况 - 价值风格评分考虑P/E、PEG等比率，突出有吸引力和被低估的股票 [3] - 增长风格评分分析预计和历史收益、销售和现金流等特征，寻找可持续增长的股票 [4] - 动量风格评分利用一周价格变化和收益预估月百分比变化等因素，指示建立高动量股票仓位的有利时机 [5] - VGM Score综合三种风格评分，按加权风格对股票评级，助投资者找到价值、增长和动量俱佳的公司，是与Zacks Rank搭配的最佳指标之一 [6] 与Zacks Rank配合 - Zacks Rank是利用收益预估修正来帮助投资者构建成功投资组合的股票评级模型，每日有超800只高评级股票 [7][8] - 选股票时应选Zacks Rank为1或2且Style Scores为A或B的，若Rank为3，Score也应为A或B以保证上行潜力 [9] - 如股票Rank为4或5，即便Style Scores为A和B，收益前景仍呈下降趋势，股价也更可能下跌 [10] 案例：United Therapeutics（UTHR） 基本情况 - UTHR在Zacks Rank中为2（买入），VGM Score为A，因其Zacks Rank和增长及VGM风格评分出色，应在投资者关注名单上 [11][12] - 公司位于马里兰州银泉市，在美国销售四种治疗肺动脉高压（PAH）的药物，包括Remodulin、Orenitram、Tyvaso和Adcirca [19] 财务表现 - 2024财年过去60天内三位分析师上调收益预估，Zacks共识预估每股增加0.45美元至24.85美元，平均收益惊喜为12.4% [20] - 公司Growth Style Score为A，预计本财年同比收益增长25.4%，适合成长型投资者 [20] Zacks研究服务 - 研究服务包括Zacks Rank和Zacks行业排名的每日更新、Zacks 1 Rank List的完全访问权、股票研究报告和高级股票筛选，助投资者更明智自信地投资 [13]

文章核心观点 - 寻找优质价值股的最佳方式是将强大的Zacks排名与风格评分系统中价值类别的出色评级相结合 ，联合治疗公司（UTHR）在Zacks排名和风格评分模型中均优于卡伦特公司（CTLT） ，价值投资者可能认为UTHR是更好的选择 [1][2] 公司对比 Zacks排名 - UTHR的Zacks排名为2（买入） ，CTLT为5（强力卖出） ，该系统强调盈利预期修正为正的公司 ，UTHR盈利前景改善程度可能更大 [3] 估值指标 - 价值类别通过多种关键指标突出被低估的公司 ，包括市盈率、市销率、盈利收益率、每股现金流等 [4] - UTHR的市净率为2.72 ，CTLT为2.90 ，市净率用于比较股票市值与账面价值 [5] - UTHR的远期市盈率为13.17 ，CTLT为49.27 ；UTHR的PEG比率为1.43 ，CTLT为1.69 ，PEG比率考虑了公司预期盈利增长率 [8] 价值评级 - 综合各项指标 ，UTHR的价值评级为B ，CTLT为D [9]

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cuttingedge growth stocks. Studies have shown that stocks with the best gro ...

Given these factors, it shouldn't be surprising that UTHR is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep United Therapeutics on your short list. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have re ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Currently, United Therapeutics has a Zacks Rank of #2 (Buy), while Catalent has a Zacks Rank of #5 (Strong Sell). This means that UTHR's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analys ...

文章核心观点 - 联合治疗公司（United Therapeutics）股价近一个月上涨11.6%，创52周新高，今年以来涨幅达46.2%，表现优于行业，结合盈利预期、估值指标、风格评分和Zacks排名等因素，其股票未来仍可能有更多涨幅 [1][11] 股价表现 - 公司股价近一个月上涨11.6%，上一交易日触及52周新高330美元，今年以来涨幅46.2%，而Zacks医疗板块涨幅7.5%，Zacks医疗-制药行业回报率为 -3.5% [1] 盈利预期 - 本财年公司预计每股收益24.85美元，营收27.1亿美元，每股收益变化25.44%，营收变化16.46%；下一财年预计每股收益27.25美元，营收28.5亿美元，同比变化分别为9.65%和5.16% [2] 风格评分 - Zacks风格评分涵盖价值、增长和动量类别，从A到F评级，还有综合VGM评分，可帮助投资者筛选股票 [3] - 公司价值评分为B，增长和动量评分均为A，VGM评分为A [9] Zacks排名 - 公司目前Zacks排名为2（买入），因覆盖分析师对盈利预期进行了有利修订 [10] 估值指标 - 公司股票当前基于本财年每股收益估计的市盈率为12.9倍，低于同行行业平均的15.2倍；基于过去现金流的市盈率为14.6倍，高于同行平均的8.7倍；PEG比率为1.4，从价值角度看未处于顶级梯队 [7] 盈利惊喜记录 - 公司过去四个季度均未低于盈利共识预期，在2024年5月1日的财报中，报告每股收益6.17美元，高于共识预期的5.63美元 [12]

United Therapeutics (UTHR) announced full enrolment in the phase III TETON 2 study evaluating a nebulized version of Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF), a scarring disease of the lungs. The TETON 2 study is now enrolled with a total of 597 patients. Top-line data from this study is expected in second-half 2025. The FDA has already approved Tyvaso as an inhalation solution (nebulized) and dry powder inhaler (DPI) for treating pulmonary arterial hypertension (PAH) and p ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. What are the Zacks Style Scores? Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance t ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...